MiR-539 inhibits the malignant behavior of breast cancer cells by targeting SP1

被引:20
|
作者
Cai, Fenglin [1 ,2 ]
Chen, Luhong [1 ,2 ]
Sun, Yuting [1 ,2 ]
He, Chunlan [1 ,2 ]
Fu, Deyuan [1 ,2 ]
Tang, Jinhai [3 ]
机构
[1] Yangzhou Univ, Clin Med Coll, Dept Gen Surg, Yangzhou 225001, Jiangsu, Peoples R China
[2] Northern Jiangsu Peoples Hosp, Yangzhou 225001, Jiangsu, Peoples R China
[3] Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Nanjing 210029, Peoples R China
关键词
miR-539; breast cancer; SP1; LUNG-CANCER; EXPRESSION; CARCINOMA; MIRNAS; PROGRESSION; BIOMARKERS; RESISTANCE; MICRORNAS; INVASION; PATHWAY;
D O I
10.1139/bcb-2019-0111
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The aberrant expression of microRNAs (miRNAs) is involved in the initiation and progression of human cancers. In our study, we found that miR-539 was down-regulated in breast cancer tissues and cell lines. Decreased expression of miR-539 was significantly associated with lymph node metastasis in patients with breast cancer. Overexpression of miR-539 inhibited the proliferation and promoted apoptosis of breast cancer cells. Moreover, highly expressed miR-539 significantly suppressed the epithelial-mesenchymal transition (EMT) and sensitized cells to cisplatin treatment. Mechanistically, miR-539 was found to target the specificity protein 1 (SP1) and down-regulated the expression of SP1 in breast cancer cells. Knockdown of miR-539 consistently increased the expression of SP1. The expression of miR-539 in breast cancer tissues was negatively correlated with the expression of SP1. Restoration of SP1 significantly attenuated the inhibitory effect of miR-539 on the proliferation of breast cancer cells. Taken together, our results indicate that miR-539 has a tumor suppressive role in breast cancer via targeting SP1, suggesting miR-539 as a promising target for the diagnosis of breast cancer.
引用
收藏
页码:426 / 433
页数:8
相关论文
共 50 条
  • [1] miR-539 suppresses the proliferation, migration, invasion and epithelial mesenchymal transition of pancreatic cancer cells through targeting SP1
    Xue, Liang
    Shen, Yan
    Zhai, Zhenglong
    Zheng, Shusen
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2020, 45 (06) : 1771 - 1782
  • [2] MiR-539 inhibits thyroid cancer cell migration and invasion by directly targeting CARMA1
    Gu, Lixue
    Sun, Weiming
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2015, 464 (04) : 1128 - 1133
  • [3] miR-539 inhibits prostate cancer progression by directly targeting SPAG5
    Hongtuan Zhang
    Shadan Li
    Xiong Yang
    Baomin Qiao
    Zhihong Zhang
    Yong Xu
    [J]. Journal of Experimental & Clinical Cancer Research, 35
  • [4] miR-539 inhibits prostate cancer progression by directly targeting SPAG5
    Zhang, Hongtuan
    Li, Shadan
    Yang, Xiong
    Qiao, Baomin
    Zhang, Zhihong
    Xu, Yong
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2016, 35
  • [5] MiR-539 inhibits cell proliferation and invasion by targeting CARMA1 in NSCLC
    Zhou, Dongbo
    He, Baimei
    Gao, Ying
    Yu, Qiao
    Chen, Qiong
    He, Bixiu
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (02): : 1460 - 1466
  • [6] MiR-539 functions as a tumor suppressor in pancreatic cancer by targeting TWIST1
    Yu, Haibo
    Gao, Ganglong
    Cai, Jing
    Song, Hongliang
    Ma, Zhongwu
    Jin, Xiaodan
    Ji, Wu
    Pan, Bujian
    [J]. EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2019, 108 : 143 - 149
  • [7] miR-539 acts as a tumor suppressor by targeting epidermal growth factor receptor in breast cancer
    Guo, Jilong
    Gong, Guohua
    Zhang, Bin
    [J]. SCIENTIFIC REPORTS, 2018, 8
  • [8] miR-539 acts as a tumor suppressor by targeting epidermal growth factor receptor in breast cancer
    Jilong Guo
    Guohua Gong
    Bin Zhang
    [J]. Scientific Reports, 8
  • [9] RETRACTED: miR-539 inhibits human colorectal cancer progression by targeting RUNX2 (Retracted Article)
    Wen, Dacheng
    Li, Songhe
    Jiang, Weidong
    Zhu, Jiaming
    Liu, Jingjing
    Zhao, Shutao
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2017, 95 : 1314 - 1320
  • [10] MED27 promotes malignant behavior of cells by affecting Sp1 in breast cancer
    Wang, Y-H
    Huang, J-H
    Tu, J-F
    Wu, M-H
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (12) : 6802 - 6808